Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia
Antimicrobial Agents and Chemotherapy · 07.05.2025 · 69 (5)
DOI: 10.1128/aac.01839-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.05.2025. Verfasst von E Ardizzoni und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Tropical Medicine, Antwerp, Belgium. Hauptthemen laut MEDLINE: Diarylquinolines, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Mycobacterium tuberculosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenian patients with multidrug-resistant TB predominantly fluoroquinolone-resistant enrolled between 2013 and 2015 in a BDQ compassionate use program. BDQ resistance at baseline and during treatment was assessed using MGIT (pDST MGIT ), minimal inhibitory concentration in 7H11 (MIC 7H11 ), and whole-genome sequencing. Risk factors, such as treatment effectiveness or stage of the disease, were analyzed for association with baseline BDQ resistance, acquired BDQ resistance, and treatment outcome. Among 39 patients, baseline BDQ resistance was 6% (2/33) by pDST MGIT and 7% (2/29) by MIC 7H11 . All four baseline isolates with an Rv0678 mutation were phenotypically resistant. During treatment, 48% of the patients acquired BDQ resistance by pDST MGIT , and 52% acquired mutations at various frequencies (97% in Rv0678 ). None of the factors significantly contributed to baseline or acquired BDQ resistance. Unfavorable treatment outcome (41%) was more frequent in the presence of acquired Rv0678 mutations [odds ratio (OR) 132, 95% confidence interval (CI) 7.43, 2375], phenotypic BDQ resistance (OR 176, 95% CI 6.48, 2423), or MIC increase above or below the critical concentration (both OR 84.3, 95% CI 2.93, 2423) during treatment. For these highly treatment-experienced patients, low baseline prevalence but high incidence of acquired BDQ resistance was observed. Acquisition of mutations in BDQ candidate resistance genes, regardless of their frequency, or increased MICs during treatment, even below the critical concentration, should be seen as a warning sign of resistance amplification and increased risk of unfavorable treatment outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Tropical Medicine, Antwerp, Belgium.
- Médecins Sans Frontières, Paris, France.
- University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Flanders, Belgium.
- National Tuberculosis Control Centre of Armenia, Yerevan, Armenia.
- National Reference Laboratory of Armenia, Yerevan, Armenia.
- Médecins Sans Frontières, Yerevan, Armenia.
ORCID-Profile: E Ardizzoni, L Rigouts
Zitieren
APA
Ardizzoni, E., Mulders, W., De Diego Fuertes, M., Hayrapetyan, A., Mirzoyan, A., Faqirzai, J., Khachatryan, N., Oganezova, I., Varaine, F., Bastard, M., Graulus, P., Meehan, C. J., Rigouts, L., de Jong, B. C., Decroo, T., Hewison, C., & Van Rie, A. (2025). Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia. Antimicrobial Agents and Chemotherapy, 69(5). https://doi.org/10.1128/aac.01839-24
Vancouver
Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A, Faqirzai J, et al. Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia. Antimicrobial Agents and Chemotherapy. 2025;69(5). doi:10.1128/aac.01839-24
BibTeX
@article{Ardizzoni2025,
author = {Ardizzoni, E and Mulders, W and De Diego Fuertes, M and Hayrapetyan, A and Mirzoyan, A and Faqirzai, J and Khachatryan, N and Oganezova, I and Varaine, F and Bastard, M and Graulus, P and Meehan, C J and Rigouts, L and de Jong, B C and Decroo, T and Hewison, C and Van Rie, A},
title = {Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {5},
doi = {10.1128/aac.01839-24}
}
EUVIMED